CareDx: 39% Revenue Growth and New Cancer Tests – The Next Phase of Growth Begins
Reading Time: 3 minutes
The transplantation test volume is growing by 21%. Medicare ensures regular cost reimbursement. The acquired cancer test NavDx is growing by 37% and is opening a new market. Two new products for 2027 and increasing revenue per test offer potential. CareDx (CDNA) develops blood tests for the early detection of organ rejection and cancer recurrence. More tests, higher test revenues, and entry into cancer diagnostics drive growth. Following the numbers from October 29, the stock rose approximately 15% in after-hours trading. Transplantation...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
